Regulatory News:
The Combined Shareholders´ Meeting of Ipsen S.A. (Paris:IPN) (Euronext: IPN ; ADR: IPSEY), chaired by Marc de Garidel, Chairman and Chief Executive Officer, was held today, in the presence of the Board of Directors and the Group Executive Committee.
The Shareholders´ Meeting approved all the resolutions submitted by the Board of Directors and in particular the distribution of a €0.80 dividend per share to be paid on 11 June 2012 (ex-dividend date 6 June 2012) and the appointment of the company Mayroy SA and Mrs. Carol Xueref, as Directors.
During the Meeting, Marc de Garidel and Susheel Surpal, Executive Vice President, Chief Financial Officer, presented, in particular, the major events and financial results for 2011 as well as the 2012 first quarter sales and outlook.
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen´s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees. Ipsen´s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
